Is dupilumab (Dupixent) indicated for a patient with poorly controlled asthma on inhaled corticosteroid and long‑acting β2‑agonist therapy who has peripheral eosinophils 20%?

Dupilumab (Dupixent) is Indicated for This Patient

Yes, dupilumab is indicated for this patient with poorly controlled asthma on inhaled corticosteroid and long-acting β2-agonist therapy, particularly given the elevated peripheral eosinophils of 20% (approximately 1000-2000 cells/μL assuming normal WBC count). 1

FDA-Approved Indication

According to the FDA label, dupilumab is approved as add-on maintenance treatment for patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma 1. The drug was studied and approved without requiring a minimum baseline blood eosinophil count, though greater efficacy is observed in patients with eosinophils ≥150 cells/μL 1.

Evidence Supporting Use

Efficacy in Eosinophilic Asthma

The pivotal QUEST trial (52 weeks, N=1902) and DRI12544 trial (24 weeks, N=776) demonstrated that dupilumab added to medium-to-high dose ICS/LABA therapy:

• Reduced severe exacerbations by 45-70% across all eosinophil subgroups 2, 3
• Improved FEV1 by 0.15-0.21 L at 12-24 weeks 2, 3
• Enhanced asthma control (ACQ-5 scores) by -0.26 to -0.35 points 2
• Showed greater benefits in patients with baseline eosinophils ≥300 cells/μL, with exacerbation reductions of 71-81% in this subgroup 3

With 20% peripheral eosinophils, this patient clearly falls into the high-responder category.

Comparison to Standard Stepwise Therapy

While older guidelines 4 recommend either increasing ICS dose or adding oral corticosteroids for severe persistent asthma uncontrolled on ICS/LABA, recent evidence shows dupilumab plus medium-dose ICS is superior to high-dose ICS plus placebo, reducing exacerbations by 70% (P<0.0001) and improving FEV1 by 0.22 L 5. This suggests dupilumab may be preferable to simply escalating ICS dose.

Clinical Algorithm for Dupilumab Initiation

Step 1: Confirm Poor Control

• Frequent symptoms requiring rescue inhaler use
• Nocturnal awakenings
• Activity limitation
• History of exacerbations requiring systemic corticosteroids

Step 2: Verify Eosinophilic Phenotype

• Blood eosinophils ≥150 cells/μL (this patient has ~1000-2000 cells/μL with 20% eosinophils) ✓
• OR FeNO ≥20-25 ppb
• Greater efficacy expected with eosinophils ≥300 cells/μL 3

Step 3: Optimize Background Therapy

• Confirm adherence to ICS/LABA
• Verify proper inhaler technique
• Address environmental triggers
• Treat comorbidities (rhinosinusitis, GERD)

Step 4: Initiate Dupilumab

• Loading dose: 400 mg or 600 mg subcutaneously (depending on age/weight) 1
• Maintenance: 200-300 mg every 2 weeks 1
• Continue background ICS/LABA therapy

Important Caveats

Safety Monitoring

1. Eosinophilia monitoring: Transient eosinophilia occurs in 47% of patients, with hypereosinophilia (>1500 cells/μL) in 19% 6. Most cases are asymptomatic, but monitor for:

   • Symptoms suggestive of EGPA (vasculitic rash, cardiac symptoms, neuropathy)
   • Persistent hypereosinophilia beyond 6 months

2. Ocular surface disorders: 8-42% incidence depending on geography 7. Higher risk with:

   • Pre-existing dry eye disease with keratitis (OR 6.3)
   • Eyelid eczema (OR 8.7)
   • Consider prophylactic artificial tears

3. Helminth infections: Complete age-appropriate vaccinations and treat any pre-existing helminth infections before starting 1

When NOT to Use as Monotherapy

Dupilumab is not indicated for acute bronchospasm or status asthmaticus 1. It is add-on maintenance therapy only. The patient must continue ICS/LABA therapy—dupilumab does not replace controller medications.

Alternative Considerations

If the patient has failed anti-IL-5/IL-5R therapy (mepolizumab, benralizumab), dupilumab remains highly effective 6. In fact, switching from anti-IL-5 to dupilumab is associated with similar or better outcomes, though hypereosinophilia may be more common in switchers 6.

Bottom Line

This patient meets FDA-approved indications for dupilumab: poorly controlled moderate-to-severe asthma on ICS/LABA with eosinophilic phenotype (20% eosinophils). The evidence strongly supports dupilumab use in this scenario, with expected reductions in exacerbations of 70-80% and meaningful improvements in lung function and quality of life 2, 5, 3. Initiate dupilumab while continuing background ICS/LABA therapy, and monitor for eosinophilia and ocular adverse events.